Ross K Macneill Foundation

What it reported doing in 2024

The ross k. Macneill foundations r33m mission is to end pediatric brain cancer. Our method to that end is to raise awareness for the diagnosis of pediatric brain cancer to inspire donations that can support research. We fund research for innovative non-toxic therapies to treat a childs tumor so that they can continue to lead healthy full and productive liives. Today a child with a brain tumor will likely not survive to see middle school. 50% of children with a brain tumor do not survive. Our dedication to funding research is because currently and for decades the nih has funded pediatric cancer research with 4% of their budget. Funding received for pediatric brain cancer research is 1% of that 4%. This has never been nor will ever be enough to fund the critical research needed. Additionally in the recent 20+ years there has never been a drug developed for children with brain cancer. The treatment children including ross receive is developed for adults and for diagnoses other than brain cancer. To understand this precisely a child with brain cancer is given treatments not made for children and not made for brain cancer. R33ms devotion to funding research is critical to saving lives of children. We work full-time to establish relationships with the leading institutions work-wide along with the leading scientists in this work to assure that our investments are with the most promising innovative owrk. Tremendous progress has been made on behalf of children and the mission of r33m is obtainable. We are privileged to do this work.

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 88.3%; rating input score 88
• Fundraising efficiency: $35.71 raised per $1 spent on fundraising; rating input score 70; 70th percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 80th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 75%; rating input score 75; 20th percentile among comparable filings
• Governance controls: 7 of 9 controls in place; rating input score 78
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -70.7%; rating input score 3; 3rd percentile among comparable filings
• Total-asset coverage ratio: 0; rating input score 1; 1st percentile among comparable filings
• Liabilities to assets ratio: Limited
• Officer compensation ratio: 38.5%; rating input score 7; 7th percentile among comparable filings

Growth

• Program expense growth: 7.2% per year; rating input score 100; 62nd percentile among comparable filings
• Revenue growth: 3.3% per year; rating input score 100; 43rd percentile among comparable filings
• Asset growth: -0.8% per year; rating input score 0; 22nd percentile among comparable filings